Cresco Labs (CRLBF) Liabilities and Shareholders Equity (2019 - 2026)

Cresco Labs has reported Liabilities and Shareholders Equity for 8 years, with the latest figure at $1.2 billion in Q1 2026.

• For the quarter ending Q1 2026, Liabilities and Shareholders Equity fell 12.11% year-over-year to $1.2 billion; the trailing twelve-month figure through Mar 2026 stood at $5.0 billion (down 7.99% YoY), and the FY2025 full-year result was $1.2 billion, down 11.66% from the prior year.
• Liabilities and Shareholders Equity for Q1 2026 stood at $1.2 billion, roughly flat from $1.2 billion in the prior quarter.
• The five-year high for Liabilities and Shareholders Equity was $1.8 billion in Q1 2022, with the low at $1.2 billion in Q4 2025.
• Historically, Liabilities and Shareholders Equity has averaged $1.4 billion across 5 years, with a median of $1.4 billion in 2025.
• Annual changes were most pronounced in 2022 — Liabilities and Shareholders Equity climbed 26.85% — and 2023, when it slipped 20.33%.
• Cresco Labs' Liabilities and Shareholders Equity stood at $1.6 billion in 2022, then retreated by 14.22% to $1.4 billion in 2023, then retreated by 0.23% to $1.4 billion in 2024, then decreased by 11.66% to $1.2 billion in 2025, then increased by 0.13% to $1.2 billion in 2026.
• The last three Liabilities and Shareholders Equity figures came in at $1.2 billion (Q1 2026), $1.2 billion (Q4 2025), and $1.3 billion (Q3 2025), per Business Quant data.